Our Team
Koen Huygens
koen.huygens@lfscnc.com 
Phone: +32 476 80 56 95 

 

Koen is an executive with over 15 years of experience managing biotech and pharmaceutical cGMP manufacturing and quality assurance operations, with a track record of successful progression of pharmaceutical development, early clinical stage to commercial operations and technology transfer of biopharmaceutical, cell-based medicinal products and medical device development.

Koen holds a PharmD and Industrial Pharmacist degree from the Universities of Leuven and Antwerp. He subsequently earned a Postgraduate Business Management degree from the University of Leuven. Koen is an Industrial Pharmacist and a registered QP in Belgium and The Netherlands.

  • LinkedIn Social Icon
Dirk De Herdt
dirk.deherdt@lfscnc.com 
Phone: +32 470 67 52 18
‚Äč

Mr. De Herdt has over 25 years of experience in the global life sciences industry, with a proven track-record in corporate strategy, product development and financing activities. He previously worked at ThromboGenics (now Oxurion) where he served as Head of Program Management, successfully advancing the company’s portfolio of projects into the next development stages. He was also instrumental in supporting financing rounds and other business development activities. Prior to ThromboGenics, Mr. De Herdt also served in senior-level development positions at TiGenix and Johnson & Johnson. He earned his PharmD degree from the University of Antwerp and received a general management training at the Vlerick Leuven Gent Management School. Mr. De Herdt is a licensed Pharmacist and Industrial Pharmacist (QP) in Belgium.

  • LinkedIn Social Icon
Peter Tomme
peter.tomme@lfscnc.com 
Phone: +32 499 77 55 63

 

Peter has over 25 years of corporate, R&D, business and executive management experience in the life sciences industry. He graduated in 1985 as a Bachelor in Chemistry from the University Ghent, Belgium, where he also earned his PhD in Biochemistry in 1991. He started his professional career at the University of British Columbia, Vancouver, Canada as a Research Staff Member specialized in Protein Engineering and the development of pharmaceutical and industrial proteins. In 1999 he co-founded Galapagos en was named R&D Director of Galapagos where he established the technology platform and target discovery in a large number of therapeutic areas. He subsequently joined Tibotec as Director R&D and was part of the drug discovery team for HIV and HCV. In 2006, he joined TiGenix as R&D Director where he was responsible for product and pipeline portfolio development. Peter also served on the Management Teams of both companies and was part of the teams that successfully concluded the IPO of Galapagos and TiGenix, respectively. More recently he has provided consultancy services to several life sciences companies. 

  • LinkedIn Social Icon

Our Team consists of seasoned professionals with in-depth expertise across all phases of product development. 

Why choose us?

Quality. 

 

Quality is part of our core DNA. Operating in a highly regulated environment, delivering high quality solutions is therefore our prime objective and commitment to our customers.

Flexibility.

 

In today's rapidly changing business landscape, where agile and creative approaches are often required, we provide development solutions that dynamically fit our customers needs, based on a deep understanding of the challenges they face.

Expertise.

 

Our senior consultants each have more than 15 years of extensive drug development experience in both large pharmaceutical companies as well as in small innovative biotechnology companies. We strongly believe in providing services with the necessary level of multi-disciplinary expertise which fully can complement our customers capabilities.

© 2020 by LFSCNC. LFSCNC is the trade name of HDH Consulting BVBA.